Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab-preliminary data

Rheumatology International

Volumn 32, Issue 5, 2012, Pages 1327-1333

  Hama, Maasa ^a   Uehara, Takeaki ^a   Takase, Kaoru ^a   Ihata, Atsushi ^a   Ueda, Atsuhisa ^a   Takeno, Mitsuhiro ^a   Shizukuishi, Kazuya ^a   Tateishi, Ukihide ^a   Ishigatsubo, Yoshiaki ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Joint destruction; PDUS; Rheumatoid arthritis; Tocilizumab

Indexed keywords

AZATHIOPRINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DOPPLER ECHOGRAPHY; FEMALE; HUMAN; JOINT DESTRUCTION; LABORATORY; MALE; OUTCOME ASSESSMENT; PARAMETERS; PATIENT MONITORING; POWER DOPPLER ULTRASONOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HAND JOINTS; HUMANS; JAPAN; KNEE JOINT; MIDDLE AGED; OBSERVER VARIATION; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER;

EID: 84863616569     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-1802-5     Document Type: Article

References (34)

1. Genovese MC, McKay JD, Nasonov EL et al (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58:2968-2980
2. Nishimoto N, Hashimoto J, Miyasaka N et al (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66:1162-1167
3. Nishimoto N, Ito K, Takagi N (2010) Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 20:222-232
4. Nishimoto N, Miyasaka N, Yamamoto K et al (2009) Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 19:12-19
5. Smolen JS, Beaulieu A, Rubbert-Roth A et al (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987-997
6. Hashimoto J, Garnero P, van der Heijde D et al. (2010) Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheu-matol. doi:10.1007/s10165-010-0325-3
7. Emery P, Keystone E, Tony HP et al (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516-1523
8. Hirabayashi Y, Ishii T, Harigae H (2010) Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice. Rheumatol Int 30:1041-1048
9. Kawashiri SY, Kawakami A, Iwamoto N et al (2010) Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics. Mod Rheumatol 20:40-45
10. Nakashima Y, Kondo M, Harada H et al (2010) Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol 20:343-352
11. Naredo E, Bonilla G, Gamero F, Uson J, Carmona L, Laffon A (2005) Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. Ann Rheum Dis 64:375-381
12. Rees JD, Pilcher J, Heron C, Kiely PD (2007) A comparison of clinical vs ultrasound determined synovitis in rheumatoid arthritis utilizing gray-scale, power Doppler and the intravenous micro-bubble contrast agent 'Sono-Vue'. Rheumatology (Oxford) 46:454-459
13. Cheung PP, Dougados M, Gossec L (2010) Reliability of ultra-sonography to detect synovitis in rheumatoid arthritis: a systematic literature review of 35 studies (1, 415 patients). Arthritis Care Res (Hoboken) 62:323-334
14. Kane D, Balint PV, Sturrock RD (2003) Ultrasonography is superior to clinical examination in the detection and localization of knee joint effusion in rheumatoid arthritis. J Rheumatol 30:966-971
15. Hameed B, Pilcher J, Heron C, Kiely PD (2008) The relation between composite ultrasound measures and the DAS28 score, its components and acute phase markers in adult RA. Rheumatology (Oxford) 47:476-480
16. Iagnocco A, Perella C, Naredo E et al (2008) Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography. Clin Rheumatol 27:491-496
17. Naredo E, Moller I, Cruz A, Carmona L, Garrido J (2008) Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum 58:2248-2256
18. Iagnocco A, Filippucci E, Perella C et al (2008) Clinical and ultrasonographic monitoring of response to adalimumab treatment in rheumatoid arthritis. J Rheumatol 35:35-40
19. Terslev L, Torp-Pedersen S, Qvistgaard E et al (2003) Effects of treatment with etanercept (Enbrel, TNRF:Fc) on rheumatoid arthritis evaluated by Doppler ultrasonography. Ann Rheum Dis 62:178-181
20. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
21. Wakefield RJ, Balint PV, Szkudlarek M et al (2005) Musculo-skeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 32:2485-2487
22. Filippucci E, Iagnocco A, Meenagh G et al (2007) Ultrasound imaging for the rheumatologist VII. Ultrasound imaging in rheumatoid arthritis. Clin Exp Rheumatol 25:5-10
23. Filippucci E, Iagnocco A, Meenagh G et al (2006) Ultrasound imaging for the rheumatologist II. Ultrasonography of the hand and wrist. Clin Exp Rheumatol 24:118-122
24. Backhaus M, Burmester GR, Gerber T et al (2001) Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 60:641-649
25. Genant HK (2001) Interleukin-1 receptor antagonist treatment of rheumatoid arthritis patients: radiologic progression and correlation of Genant/Sharp and Larsen scoring methods. Semin Arthritis Rheum 30:26-32
26. Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, Countryman PJ (1998) Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 41:1583-1590
27. Matthews JN, Altman DG, Campbell MJ, Royston P (1990) Analysis of serial measurements in medical research. BMJ 300:230-235
28. Naredo E, Collado P, Cruz A et al (2007) Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression. Arthritis Rheum 57:116-124
29. Brown AK, Conaghan PG, Karim Z et al (2008) An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 58:2958-2967
30. Smolen JS, Han C, Bala M et al (2005) Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52:1020-1030
31. Smolen JS, Van Der Heijde DM, St Clair EW et al (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54:702-710
32. Smolen JS, Han C, van der Heijde DM et al (2009) Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 68:823-827
33. Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S (2006) Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radio-graphic and patient outcomes. Arthritis Rheum 54:3119-3125
34. van der Heijde D, Klareskog L, Landewe R et al (2007) Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 56:3928-3939